Protocol for a multicenter, double-blind, randomized, placebo-controlled phase iii trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the refsal trial)

HIGHLIGHTS

• who: Dariusz Madajczak and colleagues from the (UNIVERSITY) have published the article: Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled u03b22-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial), in the Journal: (JOURNAL)

SUMMARY

@@

ACRONYMS

LAY DEFINITIONS

Licence: cc-by

Site reference: https://www.frontiersin.org/articles/10.3389/fped.2022.1060843/pdf

DOI reference:

 

If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.